Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 893.00 | |
50 mg | 6-8 weeks | $ 1,160.00 | |
100 mg | 6-8 weeks | $ 1,740.00 |
Description | Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively). |
Targets&IC50 | Gastrin/CCK-A:501 nM, Gastrin/CCK-B:0.1 nM |
In vivo | Sograzepide (0.1 μmol/kg; intravenous injection) has an inhibition effect on pentagastrin-induced gastric acid secretion in anesthetized rats (ED50: 87?nmol/kg). Sograzepide (intravenous injection; 10 μM/kg) inhibits pentagastrin-induced acid secretion (ED50: 0.0086 μM/kg). Sograzepide (intravenous injection; p.o.) in Heidenhain pouch dogs, inhibits pentagastrin-stimulated gastric acid secretion in a dose-dependent manner (ED50: 0.018 and 0.020 μM/kg, respectively) [1][2]. |
Synonyms | YM-220, Netazepide, YF 476 |
Molecular Weight | 498.58 |
Formula | C28H30N6O3 |
CAS No. | 155488-25-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (200.57 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Sograzepide 155488-25-8 Others YM 220 YM-220 Netazepide YF 476 YF476 YM220 YF-476 inhibitor inhibit